10-Q: NanoVibronix Q3 2025: Merger Boosts Revenue Amidst Losses

NanoVibronix reports increased Q3 2025 revenue driven by the ENvue merger, despite continued operating losses, a going concern warning, and product withdrawal.

Summary

• NanoVibronix completed the ENvue Medical Holdings LLC merger on February 14, 2025, significantly impacting its asset base and operations.
• The company effected two reverse stock splits: 1-for-11 on March 13, 2025, and 1-for-10 on August 11, 2025.
• Total revenues for the three months ended September 30, 2025, increased by 92% to $722 thousand, primarily due to ENvue sales.
• Total revenues for the nine months ended September 30, 2025, increased by 6% to $2,241 thousand, also driven by ENvue.
• Net income for Q3 2025 was $510 thousand, a significant improvement from a $998 thousand net loss in Q3 2024, largely due to a $3,203 thousand non-cash gain from the change in fair value of warrant liability.
• Net loss for the nine months ended September 30, 2025, increased by 135% to $5,333 thousand, compared to $2,274 thousand in the prior year.
• Gross profit margin decreased to 26% in Q3 2025 (from 35% in Q3 2024) and to 23% for 9M 2025 (from 58% in 9M 2024), impacted by inventory write-offs and lower-margin products.
• Operating expenses significantly increased for both periods, with selling and marketing up 349% in Q3 and 245% in 9M, and general and administrative up 108% in Q3 and 114% in 9M, mainly due to the ENvue merger.
• The company incurred recurring losses and negative cash flows from operations, with an accumulated deficit of $76,858 thousand as of September 30, 2025, and used $6,696 thousand in operating cash flow for the nine months.
• Management has substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• NanoVibronix withdrew the 510(k) clearance request for its PainShield MD Plus product due to identified inaccuracies and halted future sales, recording a $119 thousand inventory allowance.
• The company successfully raised capital through various offerings, including Series G and H Convertible Preferred Stock and a September 2025 Registered Direct Offering, providing $17.1 million in net proceeds from equity financings for the nine months.
• Material weaknesses in internal control over financial reporting were identified, and remediation efforts are underway.
• The company's prior independent registered public accounting firm, Zwick CPA, PLLC, was dismissed due to potential proceedings against them, posing a risk to future filings and financings.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, evidenced by recurring and increasing net losses, negative operating cash flow, and a stated going concern warning. Operational setbacks include a product withdrawal and declining gross margins. While capital raises have provided liquidity, they come with significant dilution and restrictive covenants. Governance issues, such as material weaknesses in internal controls and the dismissal of the auditor, add to the high-risk profile. The Q3 net income is misleading due to a non-cash accounting gain.

Positives

• Total revenues increased by 92% to $722 thousand for the three months ended September 30, 2025, compared to $376 thousand in the prior year, primarily due to the ENvue merger.
• Total revenues increased by 6% to $2,241 thousand for the nine months ended September 30, 2025, compared to $2,114 thousand in the prior year, driven by ENvue sales.
• The ENvue Medical Holdings LLC merger was successfully completed on February 14, 2025, expanding the company's product portfolio into enteral feeding.
• Net income for the three months ended September 30, 2025, was $510 thousand, a significant improvement from a net loss of $998 thousand in the same period of 2024.
• Cash and cash equivalents increased to $6,950 thousand as of September 30, 2025, from $752 thousand as of December 31, 2024, largely due to financing activities.
• The company successfully raised $17.1 million in net proceeds from the issuance of common stock, preferred stock, and warrants during the nine months ended September 30, 2025.

Negatives

• The company incurred a net loss of $5,333 thousand for the nine months ended September 30, 2025, a 135% increase from the $2,274 thousand net loss in the prior year.
• Gross profit as a percentage of revenues significantly decreased to 23% for the nine months ended September 30, 2025, from 58% in the prior year, partly due to inventory write-offs and lower-margin products.
• Operating expenses saw substantial increases, with selling and marketing up 245% to $1,878 thousand and general and administrative up 114% to $4,997 thousand for the nine months ended September 30, 2025.
• The company used $6,696 thousand in cash from operating activities for the nine months ended September 30, 2025, indicating continued negative operational cash flow.
• An accumulated deficit of $76,858 thousand as of September 30, 2025, highlights ongoing financial losses.
• Management has substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• The 510(k) clearance for the PainShield MD Plus product was withdrawn due to inaccuracies, leading to a halt in future sales and a $119 thousand inventory write-down.
• Material weaknesses in internal control over financial reporting were identified, indicating deficiencies in financial reporting processes.
• The prior independent registered public accounting firm, Zwick CPA, PLLC, was dismissed due to potential proceedings, which could lead to significant delays and additional costs for SEC filings and financings.
• The company is facing an arbitration award of approximately $2.2 million (including interest) to Protrade Systems, Inc., which is currently under appeal.

Risks

• The Series H Certificate of Designations provides for cumulative dividends payable in common stock, which will result in dilution to shareholders and may strain the company's ability to satisfy obligations if sufficient shares are not available.
• Anti-dilution provisions in the Series H Certificate of Designations may further dilute shareholder interests, depress the common stock price, and make it difficult to raise additional capital.
• Restrictive covenants in the Series H Purchase Agreement may limit the company's ability to procure additional financing on acceptable terms or at all, potentially requiring waivers from investors.
• The dismissal of the prior independent registered public accounting firm, Zwick CPA, PLLC, due to potential proceedings, may cause material expenses, delays in financings or SEC filings, and negatively impact the stock price and access to capital markets.
• The company's ability to continue as a going concern is in substantial doubt due to recurring losses and negative cash flows from operations, requiring additional funding which may not be available on favorable terms.
• Future operating results are subject to quarterly variations based on distributor ordering patterns, regulatory approvals, clinical trial phases, manufacturing efficiencies, and geopolitical factors.
• Increased tariffs, hostilities in Israel and the Middle East, and currency fluctuations (Euro, New Israeli Shekel vs. U.S. dollar) could adversely impact manufacturing costs, trade, and financial results.
• The company is subject to risks common in the biopharmaceutical industry, including completing studies and clinical trials, obtaining regulatory approvals, competition, dependence on key personnel, protecting proprietary technology, and compliance with government regulations.
• Ongoing geopolitical conflicts (Russia-Ukraine, Israel-Hamas) and rising global inflation could adversely impact macroeconomic conditions, market volatility, and the company's business and operations.
• Changes to U.S. policy by the U.S. Congress or any new administration could impact the U.S. and global economy, tariffs, trade relations, and the regulatory environment, potentially affecting the business.

Future Outlook

The company expects to incur future net losses and negative cash flows from operations. Its transition to profitability is dependent upon achieving adequate revenues to support its cost structure. The company intends to fund future operations through cash on hand, additional private and/or public offerings of debt or equity securities, or a combination thereof. There are no assurances that adequate financial resources will be obtained.

Management Comments

• Management believes that the estimates, judgments, and assumptions used in preparing the consolidated financial statements are reasonable based upon information available at the time they are made.
• Management has substantial doubt regarding the Company's ability to continue as a going concern for twelve months from the date of issuance of these interim condensed consolidated financial statements.
• The increase in revenue is primarily attributable to the addition of sales from ENvue products, partially offset by a decline in sales of Nanovibronix products to its largest customer during the quarter.
• The decrease in gross profit was primarily driven by lower sales volumes of PainShield Plus, which has historically generated higher gross margins, and inventory write-offs related to PainShield Plus.
• The increase in R&D expenses was mainly due to the costs of our clinical trial test program with the University of Michigan and the inclusion of expenses from ENvue's operations.
• The increase in selling and marketing expenses was primarily due to the inclusion of ENvue's operations following the ENvue Merger.
• The increase in general and administrative expenses was primarily due to professional fees incurred in connection with the ENvue Merger and the inclusion of ENvue's operations.

Industry Context

NanoVibronix operates in the medical device sector, specializing in non-invasive biological response-activating devices for wound healing and pain therapy. The acquisition of ENvue Medical Holdings LLC expands its focus into enteral feeding medical equipment. The merger was undertaken to combine and enhance respective strengths, indicating a strategic move towards diversification and market expansion within the broader medical device industry.

Management Changes

Corporate Governance

Legal Proceedings

• An ongoing appeal against an arbitration award of approximately $2.2 million (including interest) to Protrade Systems, Inc. for alleged failure to supply patches for the DV0057 Painshield MD device. Oral arguments were presented on May 30, 2025, with a decision expected later this year.

Related Party Transactions

• Alpha Capital Anstalt: Issued a Consolidated Secured Note (Alpha Note) to Alpha for $2,497 thousand on January 17, 2025. Entered into a PIPE Purchase Agreement for a $500 thousand senior convertible debenture on February 13, 2025, which was later amended to $1,300 thousand. ENvue issued a $360 thousand promissory note to Alpha on April 11, 2025, guaranteed by the company.
• Pierson Ferdinand LLP: Paid $58 thousand for legal services related to Protrade litigation for the nine months ended September 30, 2025. This firm was joined by former director Aurora Cassirer's legal team.
• Doron Besser and Zeev Rotstein: Appointed to the Board of Directors on February 14, 2025, in connection with the ENvue Merger, and entered into standard indemnification agreements with the company.

Stakeholder Impact

• Shareholders: Significant dilution from multiple capital raises (Series G, X, H Preferred Stock, Registered Direct Offering), reverse stock splits, and potential future conversions. Risk of depressed stock price due to dilution and anti-dilution provisions. Exposure to potential delisting from Nasdaq due to past non-compliance and ongoing monitoring. Uncertainty regarding the going concern status and the impact of auditor dismissal.
• Employees: Severance pay fund maintained for Israeli employees. Potential impact on morale and retention due to financial instability and operational changes.
• Customers: Halt of future sales for PainShield MD Plus product due to 510(k) withdrawal may impact customer access to this specific product. ENvue merger aims to expand product offerings in enteral feeding.
• Creditors: The company's going concern warning and accumulated deficit raise concerns about its ability to meet future obligations, although recent capital raises have improved short-term liquidity.
• Suppliers: Potential impact on payment terms or future business relationships due to financial condition and operational changes.

Next Steps

• Hold a meeting of stockholders to seek approval under Nasdaq Stock Market Rule 5635(d) for the issuance of common stock related to Series H Preferred Stock and warrants, and hold subsequent meetings every four months if approval is not obtained.
• File the Resale Registration Statement as soon as reasonably practicable for the shares of common stock underlying the Series H Preferred Stock and Series H Warrants.
• Continue remediation efforts to address material weaknesses in internal control over financial reporting, including formalizing risk assessment, implementing revised control activities, and expanding consultations with third-party specialists.
• A decision is expected at an undetermined date later this year regarding the appeal of the $2.2 million arbitration award to Protrade Systems, Inc.
• The Second Closing of the July 2025 Private Placement was consummated on October 30, 2025, involving the issuance of additional Series H Preferred Stock and warrants.

Key Dates

Recommendation

The company faces severe fundamental challenges, including a stated 'going concern' warning, substantial and increasing net losses, and persistent negative operating cash flow. The withdrawal of a key product (PainShield MD Plus) and declining gross margins indicate operational distress. While recent capital raises have provided a temporary cash infusion, they have come at the cost of significant shareholder dilution and introduce restrictive covenants. The identified material weaknesses in internal controls and the dismissal of the independent auditor raise serious governance and financial reporting concerns. The Q3 net income is misleading, primarily driven by a non-cash accounting adjustment. Given the high level of financial risk, operational setbacks, and governance issues, a seasoned investor would likely recommend a strong sell, as the long-term viability and shareholder value are highly questionable.

Keywords

NanoVibronix, ENvue Medical Holdings, Medical Device, Q3 2025, SEC Filing, Merger, Reverse Stock Split, Preferred Stock, Warrants, Capital Raise, Going Concern, PainShield MD Plus, FDA Withdrawal, Internal Controls, Auditor Dismissal, Financial Results, Biopharmaceutical Industry, Enteral Feeding, Wound Healing, Pain Therapy